Default company panoramic image
Dff83ee4 ba56 4f2e 8537 e2a2b2c07bae

Kereos Inc.

A biopharmaceutical company with targeted nanoparticles for use with existing and new drugs for enhanced performance.

  • Stage Product In Development
  • Industry Biotechnology
  • Location St. Louis, MO, USA
  • Currency USD
  • Employees 5
  • Website

Company Summary

Kereos is a biopharmaceutical company that has developed a nanoparticle drug delivery technology that enables targeted delivery of a broad range of therapeutic drug compounds, including existing drugs, new drug candidates and compounds that are too toxic or too fragile to be delivered without the protection and targeting offered by the Kereos technology.


  • Default avatar
    John Hefti
    EVP of Business Development and Strategic Planning

    Dr. Hefti is an experienced entrepreneur in both the life sciences and technology sectors. He has 14 issued US patents and 18 patent applications pending. Along with other senior management, he raised over $64M in venture investments for previous companies, and completed licensing deals worth over $300M. He studied mathematics and physics as an undergraduate (Columbia University) and graduate student (UC Berkeley), and has an MD from Stanford

Previous Investors

  • Default avatar
    Prolog Ventures
    Default avatar
    Charter Life Sciences
    Default avatar
    MB Ventures